



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

**Oversight Committee Meeting Minutes
August 21, 2019**

019

NOTE: Unless the information is confidential, the reports, presentations, and grant award information referenced in the minutes are available at <http://ocmeetings.cprit.texas.gov> in the "Oversight Committee Board Packet" section for the corresponding meeting date.

Call to Order – Agenda Item 1

A quorum being present, Presiding Officer Will Montgomery called the Oversight Committee to order at 9:16 a.m.

Roll Call/Excused Absences – Agenda Item 2

Committee Members Present

Angelos Angelou
David Cummings, M.D.
Donald (Dee) Margo
Will Montgomery
Mahendra Patel, M.D.
Bill Rice, M.D.
Craig Rosenfeld, M.D.

Adoption of Minutes from the May 15, 2019 Meeting – Agenda Item 3 – Tab 1

MOTION:

On a motion by Dr. Bill Rice and seconded by Angelos Angelou, the Oversight Committee unanimously voted to approve the minutes of the Oversight Committee meeting of May 15, 2019, as presented.

Public Comment

There were no requests to provide public comment.

Presiding Officer Montgomery expressed CPRIT's condolences to the City of El Paso and recognized Vice Presiding Officer Dee Margo's efforts to guide the community through its recent tragedy.

Grantee Presentation – Agenda Item 5, Tab 2

Presiding Officer Montgomery recognized Chief Scientific Officer Dr. James Willson to introduce Funda Meric-Bernstam, M.D., Department Chair, Department of Investigational Cancer

Therapeutics, The University of Texas M.D. Anderson Cancer Center. Dr. Meric-Bernstam presented her CPRIT-funded Core Facility Support Award, “Precision Oncology, Decision Support Core.”

Chief Executive Officer Report – Agenda Item 6, Tab 3

Mr. Roberts provided an update on personnel and the amount of funds available.

Chief Compliance Officer Report and Compliance Certification of Grant Award Process – Agenda Item 7, Tab 4

Chief Compliance Officer Vince Burgess presented the Compliance Report for the past quarter’s activities. He reported the completion of the Annual Grantee Risk Assessment for FY 2020.

Mr. Burgess also presented the Compliance Certification for the proposed grant awards. He certified compliance with all applicable state and agency requirements for the proposed academic research grant awards, prevention grant awards, and the product development grant awards.

Chief Scientific Officer Report and Award Recommendations – Agenda Item 8, Tab 5

Presiding Officer Montgomery recognized Dr. Willson to present the academic research award recommendations and the program update.

Dr. Willson referred members to Table 1 on page 8 of the Proposed Grant Award booklet and presented the academic research award slates recommended by the Scientific Review Council (SRC) and the Program Integration Committee (PIC). The slates included applications from Cycles 19.1, 19.2 and recruitment cycles 19.10, 19.11 and some from 19.12. Dr. Willson noted that the PIC previously deferred the ten applications from cycle 19.1 that it now recommends for funding. He also reported that three recruitment applications recommended by the SRC/PIC were subsequently withdrawn by the applicants, resulting in 58 recommended awards totaling \$94,929,894.

Table 1: SRC and PIC Recommended Awards for Fiscal Year Review Cycle 2019.2*

Rank	Application ID	Award Mechanism	Score	Application Title	PI	PI Organization	Recommended Budget
1	RP190522	ETRA	1.8	Novel Endoscope-Cleaning Port for Minimally Invasive Cancer Surgery	Burt, Bryan M	Baylor College of Medicine	\$1,349,759
2	RP190674	CFSA	1.8	Business-Driven Accelerator for Cancer Therapeutics (BDACT)	McKeon, William	Texas Medical Center	\$5,440,894
3	RP190641	CAP-CAC	1.8	The Texas Collaborative Center for Hepatocellular Cancer	El-Serag, Hashem	Baylor College of Medicine	\$3,000,000

4	RP190570	HIHRRRA	2.0	Expression Landscape and Biomedical Significance of Transfer RNAs in Cancer	Han, Leng	The University of Texas Health Science Center at Houston	\$199,998
5	RP190602	CFSA	2.0	New Capabilities for Cancer Research in the TMC CryoEM Cores	Ludtke, Steven J	Baylor College of Medicine	\$5,381,089**
6	RP190682	CFSA	2.1	A Targeted Proteomics and Metabolomics Mass Spectrometry Core Facility at the University of Texas Medical Branch at Galveston	Russell, William K	The University of Texas Medical Branch at Galveston	\$3,550,923
7	RP190579	HIHRRRA	2.2	Novel High-Throughput Microfluidic Device for Isolating T Cells Directly From Whole Blood to Simplify Manufacturing of Cellular Therapies	Shevkoplyas, Sergey	University of Houston	\$200,000
8	RP190599	HIHRRRA	2.2	Epithelial Memory of Resolved Inflammation as a Driver of Pancreatic Cancer Progression	Viale, Andrea	The University of Texas M. D. Anderson Cancer Center	\$199,804
9	RP190617	CFSA	2.3	High-Performance Mass Spectrometry Imaging Core Facility	Brodbelt, Jennifer	The University of Texas at Austin	\$3,794,611
10	RP190513	CAP-RA	2.3	Patient-Centered Liver Cancer Prevention in the Houston Community	Hwang, Jessica	The University of Texas M. D. Anderson Cancer Center	\$2,456,676
11	RP190672	HIHRRRA	2.4	Alleviating SN-38-Induced Late-Onset Diarrhea by Preserving Local UGTs in the Colon	Gao, Song	Texas Southern University	\$200,000

12	RP190581	CFSA	2.4	Gulf Coast Consortium High-Throughput Flow Cytometry Program (HtFCP)	Martinez-Moczygemba, Margarita	Texas A&M University Health Science Center Institute of Biosciences and Technology	\$4,690,019***
13	RP190561	CFSA	2.5	Advanced Cancer Antibody Drug Modalities Core Facility	An, Zhiqiang	The University of Texas Health Science Center at Houston	\$6,000,000
14	RP190567	HIHRA	2.5	Targeting Cancer-Associated Fibroblasts With Anti-IL-11-Secreting CAR T Cells	Parihar, Robin	Baylor College of Medicine	\$199,920
15	RP190658	ETRA	2.6	Engineering a Prototype for Label-Free Separation and Staining-Free Detection of Circulating Tumor Cells	Vanapalli, Siva A	Texas Tech University	\$657,222
16	RP190542	ETRA	2.6	Discovery and Development of Novel Peptibody-Drug Conjugate for Treating Cancers of the Digestive System	Liu, Qingyun	The University of Texas Health Science Center at Houston	\$2,000,000
17	RP190610	ETRA	2.7	Development of an Antibody Targeting PCDH7 for Lung Cancer Therapy	O'Donnell, Kathryn A	The University of Texas Southwestern Medical Center	\$1,999,998
18	RP190678	HIHRA	2.9	Radioactive Nanoseeds for Eradicating Glioblastoma Without Crossing Blood-Brain Barrier	Hao, Yaowu	The University of Texas at Arlington	\$198,039
19	RP190653	HIHRA	2.9	Nanosized Immunotherapies to Access and Treat Pediatric Medulloblastoma	Maynard, Jennifer A	The University of Texas at Austin	\$200,000

20	RP190587	HIHRRRA	2.9	Development of a Minipig Glioma Model and Validation of Human Clinical Relevance	Rostomily, Robert	The Methodist Hospital Research Institute	\$200,000
21	RP190534	HIHRRRA	3.0	Mechanism-Based Targeting of Core Module of the BAF Complex in Cancer	Gupta, Yogesh K	The University of Texas Health Science Center at San Antonio	\$199,996
22	RP190588	ETRA	3.1	Smart Surgical Microscope Powered by AI Technology and Hyperspectral Imaging	Fei, Baowei	The University of Texas at Dallas	\$1,592,405
23	RP190669	HIHRRRA	3.1	A Novel Cellular-Level Imaging Approach to Assess Payload Drug Distribution in Tumors Following Administration of Targeted Drug Delivery Systems	Prideaux, Brendan	The University of Texas Medical Branch at Galveston	\$199,996
24	RP190612	HIHRRRA	3.1	Real-Time Analyses of Metabolic Synergy Between Cancer and Stromal Cells by Optogenetic Control of Cell Signaling	Wang, Fen	Texas A&M University System Health Science Center	\$200,000
25	RP190497	HIHRRRA	3.1	Topical Esomeprazole for Radiation-Induced Dermatitis	Ghebre, Yohannes T	Baylor College of Medicine	\$199,500
26	RP190507	CFSA	3.2	Recombinant Antibody Production Core (RAPC) at Science Park	McBride, Kevin	The University of Texas M. D. Anderson Cancer Center	\$3,505,385
27	RP190524	CFSA	3.2	TTUHSC Cancer Animal Facility	Trasti, Scott L	Texas Tech University Health Sciences Center	\$3,183,703
28	RP190539	HIHRRRA	3.3	Therapeutic Targeting of EWS-FLI1	Kittler, Ralf	The University of Texas Southwestern Medical Center	\$200,000

				Turnover in Ewing Sarcoma			
29	RP190560	HIHRA	3.3	Development of a Novel Class of PRC2 Inhibitors Comprising Mirror Image RNA	Sczepanski, Jonathan T	Texas A&M University	\$200,000
30	RP190527	HIHRA	3.3	Targeting ROR-gt:IL-17 Pathway to Inhibit Colon Cancer	Poojary, Venuprasad K	Baylor Research Institute	\$199,942
31	RP190592	HIHRA	3.4	Chemoprevention of Acquired Therapeutic Resistance and Disease Recurrence in Ovarian Cancer	Palle, Komaraiah	Texas Tech University Health Sciences Center	\$200,000
32	RP190556	HIHRA	3.6	Targeting ARNT and RBFOX2 Alternative Splicing as a Novel Treatment Modality in Lymphoid Malignancies	Wright, Casey W	The University of Texas Medical Branch at Galveston	\$200,000
33	RP190655	HIHRA	3.6	Mechanisms of Exosomal Cell Entry and Signaling in Cancer	PELLOIS, JEAN-PHILIPPE	Texas AgriLife Research	\$200,000

*This table includes ten award recommendations from review cycle 19.1 that the PIC previously deferred.

**RP190602 reflects budget as reduced by the SRC. SRC recommended the reduction in funding of personnel.

*** RP190581 reflects budget as reduced by the SRC. SRC recommended reduction in consumables.

Table 2: SRC and PIC Recommendations for Recruitment Cycles: FY19.10 and FY19.11

Rank	App ID	Candidate	Mechanism	Organization	Budget	Overall Score
1	RR190070	Tobias Meyer, Ph.D.	REI	The University of Texas Southwestern Medical Center	\$6,000,000	1.0
2	*RR190072	Benjamin Izar, Ph.D.	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
3	RR190069	Stanley Lee, Ph.D.	RFTFM	Baylor College of Medicine	\$2,000,000	1.0
4	RR190087	Gerta Hoxhaj, Ph.D.	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
5	RR190078	Mackenzie Wehner, M.D.	RFTFM	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.2

6	RR190080	William Jorgensen, Ph.D.	REI	Texas Tech University	\$6,000,000	1.2
7	RR190065	Vicky Yao, Ph.D.	RFTFM	Rice University	\$1,669,997	1.4
8	RR190090	Benjamin R. Sabari, Ph.D.	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	1.7
9	*RR190067	Eunhee Choi, Ph.D.	RFTFM	The University of Texas Health Science Center at Houston	\$2,000,000	2.0
10	RR190071	Jian Zhou, Ph.D.	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
11	RR190077	Kevin Nead, M.D.	RFTFM	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	2.0
12	*RR190066	Ritchie Chen, Ph.D.	RFTFM	Rice University	\$2,000,000	2.0
13	RR190089	Unmesh Jadhav, Ph.D.	RFTFM	Baylor College of Medicine	\$2,000,000	2.0
14	RR190091	Piya Ghose, Ph.D.	RFTFM	The University of Texas at Arlington	\$2,000,000	2.0
15	RR190076	Mary Teruel, Ph.D.	RRS	The University of Texas Southwestern Medical Center	\$4,000,000	2.6
16	RR190079	Christopher Flowers, MD.	REI	The University of Texas M. D. Anderson Cancer Center	\$6,000,000	2.8

* Withdrawn by applicant following SRC/PIC recommendation

Table 3: Scientific Review Council Recommendations for Recruitment Cycle 19.12

Rank	App ID	Candidate	Mechanism	Organization	Budget	Overall Score
1	RR190096	Taylor, Alison	RFTFM	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
2	RR190104	Li, Ang	RFTFM	Baylor College of Medicine	\$2,000,000	1.3
3	RR190081	Lu , Jiaozhi (George)	RFTFM	Rice University	\$2,000,000	2.0
4	RR190101	Weyemi, Urbain	RFTFM	The University of Texas at Austin	\$2,000,000	2.0
5	RR190106	Sreelatha, Anju	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	2.3

Conflict of Interest Notification

Presiding Officer Montgomery noted for the record that no Oversight Committee members reported conflicts of interest with any proposed academic research awards.

Approval Process – Academic Research Awards

Following the Oversight Committee's agreement to take up the ten academic research award slates together in one vote, Presiding Officer Montgomery called for a vote on the award recommendations.

MOTION:

On a motion made by Mr. Angelou and seconded by Dr. Rice, all Oversight Committee members present and able to vote unanimously approved the PIC's recommendations for the ten academic research award slates.

MOTION:

On a motion made by Vice Presiding Officer Margo and seconded by Dr. Rice, all Oversight Committee members voted to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

After the award recommendation votes, Dr. Willson presented the academic research program update, referring the members to pages 5.1 – 5.5 of the meeting book. He provided an overview of the proposed RFAs and RFA schedules for review cycle 20.2. He noted one of the proposed RFAs, the Early Clinical Investigator Award, is a new mechanism and represents CPRIT's investment in clinical investigators. Dr. Willson also noted a decrease in the funding cap for the Core Facility Support Awards for the cycle 20.2 RFA and an increased funding cap for the cycle 20.2 High Impact/High Risk RFAs.

MOTION:

On a motion made by Dr. Rice and seconded by Vice Presiding Officer Margo, the Oversight Committee unanimously voted to approve the proposed timeline and Academic Research Program RFAs for the second cycle of FY 2020.

Chief Product Development Officer Report and Award Recommendations – Agenda Item 9, Tab 6

Presiding Officer Montgomery recognized Chief Product Development Officer Dr. Cindy WalkerPeach to present the proposed product development research award recommendations and to provide an update on the product development program.

Dr. WalkerPeach presented the PIC's three product development award recommendations, including award contingencies, totaling \$25,874,543 for review cycles 19.1 and 19.2: OncoNano Medicine, Inc., Perimeter Medical Imaging Corporation and Rapamycin Holdings, Inc. She reminded members that one applicant, DP190046, withdrew its application from consideration after the PDRC submitted its recommendations.

An Oversight Committee member asked if Perimeter Medical Imaging Corporation’s technology was related to Dr. Livia’s Eberlin’s CPRIT-funded research. Dr. WalkerPeach confirmed that it was not related.

Compliance Certification

Presiding Officer Montgomery reminded members that Mr. Burgess previously certified compliance of the product development awards process.

Presiding Officer Montgomery informed members of his conflict of interest with DP190066, a proposed product development award recommendation for OncoNano Medicine, and requested that Vice Presiding Officer Margo preside over the vote and discussion of that proposed award.

Approval Process – Product Development Research Awards

Rank	App ID	Mechanism	Company Name	Project	Score	Maximum Budget
1	DP190066	TXCO (19.2)	OncoNano Medicine, Inc.	Tumor-Specific T-Cell-Activating Cancer Vaccines for Immunotherapy of Solid Tumors Including HPV	2.1	\$15,427,699
2	DP190087	RELCO (19.2)	Perimeter Medical Imaging Corporation	OTIS (Optical Tissue Imaging System) Impact on Final Positive Margin Rates in Breast-Conserving Surgery	3.2	\$7,446,844
3	DP190069	SEED (19.2)	Rapamycin Holdings, Inc.	Emtora Biosciences - using eRapa to treat Familial Adenomatous Polyposis (FAP)	3.2	\$3,000,000

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee voted to unanimously approve the PIC’s recommendation for Perimeter Medical Imaging and Rapamycin Holdings, including the contingencies described by Dr. WalkerPeach.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee voted to approve the PIC’s recommendation for OncoNano Medicine, including the contingency described by Dr. WalkerPeach.

Vice Presiding Officer Margo noted for the record that Presiding Officer Montgomery did not participate in the discussion or vote for OncoNano Medicine.

MOTION:

On a motion made by Dr. Rice and seconded by Dr. Patel, all Oversight Committee members voted to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

MOTION:

On a motion made by Dr. Rice and seconded by Vice Presiding Officer Margo, the Oversight Committee unanimously voted pursuant to the General Appropriations Act, Article IX, Section 4.03(a) to authorize CPRIT to disburse grant funds via advance payments to DP190066, DP190087 and DP190069 upon execution of the award contracts and the successful completion of tranches.

Following the awards, Dr. WalkerPeach updated the Oversight Committee on the status of applications under review in the 20.1 cycle and notified members of the expansion of the Product Development Review Council by one member. Dr. WalkerPeach finished her report with the presentation of the proposed review timeline and three product development RFAs for the second cycle of FY 2020.

MOTION:

On a motion made by Dr. Rice and seconded by Vice Presiding Officer Margo, the Oversight Committee unanimously voted to approve the proposed timeline and Product Development Research Program RFAs for the second cycle of FY 2020.

Chief Prevention Officer Report – Agenda Item 10, Tab 7

Chief Prevention Officer Ramona Magid updated members on the Prevention Program activities and presented the ten prevention program projects, representing four grant mechanisms, recommended by the Prevention Review Council and PIC for award funding totaling \$14,497,981. Ms. Magid reported that all the recommended applications address one or more of the Prevention Program activities.

An Oversight Committee member asked if the recommended award focused on tobacco prevention in a medically underserved pediatric population would include education and awareness about electronic vapor product use; Ms. Magid responded that the project would address these topics.

Compliance Certification

Presiding Officer Montgomery reminded members that Mr. Burgess previously certified compliance of the prevention awards process.

Approval Process – Prevention Grant Awards

After the Oversight Committee agreed to consider the four slates together, Presiding Officer Montgomery called for a vote on the proposed award recommendations.

Cycle 19.2 Recommended Prevention Program Awards

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP190061	EPS	Salud en Mis Manos: Delivering Evidence-Based Breast & Cervical Cancer Prevention Services to Latinas in Underserved Texas South and Gulf Coast Communities	Savas, Lara S	The University of Texas Health Science Center at Houston	1.0	1	\$1,999,953
PP190070	EPS	Expanding Colorectal Cancer Screening Throughout East Texas	McGaha, Paul	The University of Texas Health Center at Tyler	2.3	2	\$1,952,724
PP190052	TCL	Integrated lung cancer screening and tobacco cessation in an urban safety-net system	Gerber, David E	The University of Texas Southwestern Medical Center	2.5	3	\$999,998
PP190080	DI	The Dissemination of a Genetic Navigation Framework for Hereditary Cancers to Increase Mutation Carrier Identification and Improve Outcomes	Ross, Theodora S	The University of Texas Southwestern Medical Center	2.7	4	\$295,453
PP190063	TCL	Centralized outreach to promote smoking cessation and lung cancer screening in vulnerable adult patients in a safety net system	Pignone, Michael	The University of Texas at Austin	3.1	5	\$999,962
PP190051	EPS	Expanding a Community Network for Cancer Prevention to Increase HPV Vaccine Uptake and Tobacco Prevention in a Medically Underserved Pediatric Population	Montealegre, Jane R	Baylor College of Medicine	3.3	6	\$1,287,834
PP190055	EPS	Expansion of the Building a Healthy Temple Cancer Prevention Program in Bexar County and Rio Grande Valley	He, Meizi	The University of Texas at San Antonio	3.4	7	\$1,999,503
PP190058	EPS	TIEMPO de VACUNARTE (TIME TO GET VACCINATED) 2	Molokwu, Jennifer C	Texas Tech University Health Sciences Center at El Paso	3.4	8	\$1,963,826
PP190075	EBP	Increasing Breast and Colorectal Cancer Screening Rates for the Medically Underserved using Population Health Strategies at a Multi-County FQHC	Flash, Charlene	Legacy Community Health Services	3.7	9	\$999,276
PP190043	EPS	Empower Her to Care Expansion (FY2020-FY2021): Increasing Access to Breast Cancer Screening and the Continuum of Care for Underserved Texas Women	Joseph, Bernice	The Rose	3.7	10	\$1,999,452

EBP: Evidence-Based Cancer Prevention Services

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

TCL: Tobacco Control and Lung Cancer Screening

DI: Dissemination of CPRIT-Funded Cancer Control Interventions

MOTION:

On a motion made by Dr. Rice and seconded by Vice Presiding Officer Margo, the Oversight Committee unanimously voted to approve the PIC’s recommendation for the ten prevention awards.

MOTION:

On a motion made by Vice Presiding Officer Margo and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

Following the vote on the award recommendations, Ms. Magid presented the proposed schedule and RFAs for the second cycle of FY 2020 (page 7-2) for consideration. The proposed RFAs in the schedule include Evidence-Based Cancer Prevention Services, Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations, and Tobacco Control and Lung Cancer Screening.

MOTION:

On a motion made by Vice Presiding Officer Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the Prevention Program's plan for proposed RFAs for the second cycle of FY 2020.

Internal Auditor Report – Agenda Item 11, Tab 8

Presiding Officer Montgomery recognized CPRIT internal auditor Dan Graves with Weaver and Tidwell. Mr. Graves directed the committee (beginning on page 8-2 of the meeting book) to the *Internal Audit Follow-Up Procedures Report over Procurement and P-Cards* and summarized the status of procurement and P-cards and the FY 2020 Internal Audit Plan.

An Oversight Committee member had a question regarding information security considering the recent increase in ransomware activity and Mr. Graves responded that there were no open findings.

MOTION:

On a motion by Dr. Rice and seconded by Dr. Patel, the Oversight Committee unanimously voted to approve the *Internal Audit Follow-Up Procedures Report over Procurement and P-Cards*.

MOTION:

On a motion by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the FY 2020 Internal Audit Plan.

Scientific Research and Prevention Program Committee Appointments – Agenda Item 12, Tab 9

Presiding Officer Montgomery recognized Mr. Roberts to present his eight Scientific Research and Prevention Program Committee Appointments.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the eight Scientific Research and Prevention Program Committee Appointments.

Advisory Committee Appointments – Item 13, Tab 10

Presiding Officer Montgomery recognized Mr. Roberts to present CPRIT's appointments to the Clinical Trials Advisory Committee and the Product Development Advisory Committee. Mr. Roberts also noted that Dr. Wood has joined the University Advisory Committee representing Baylor University.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the appointments to the Clinical Trials and Product Development Advisory Committees.

FY 2020 Honoraria Policy – Item 14, Tab 11

Presiding Officer Montgomery recognized Mr. Roberts to present the FY 2020 CPRIT Honoraria Policy.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the FY 2020 CPRIT Honoraria Policy.

Health & Safety Code Section 102.1062 Waivers – Item 15, Tab 12

Presiding Officer Montgomery recognized Mr. Roberts to present four Health & Safety Code Section 102.1062 waivers for FY 2020. Noting that one of the proposed waivers addresses his conflicts of interest, Presiding Officer Montgomery reported that he would not vote on the waivers and asked Vice Presiding Officer Margo to preside over the vote.

Vice Presiding Officer Margo called for a vote on the proposed waivers.

MOTION:

On a motion made by Dr. Rosenfeld and seconded by Dr. Rice, all Oversight Committee members present and able to vote approved the four proposed Health and Safety Code § 102.1062 waivers. Vice Presiding Officer Margo noted for the record that Presiding Officer Montgomery did not participate in the vote.

Resolution Transferring Management Authority to the Texas Treasury Safekeeping Trust Company – Item 16, Tab 13

The chair recognized Deputy Executive Officer and General Counsel, Kristen Doyle to explain the proposed resolution transferring asset management authority of AlloVir, formerly ViraCyte, to the Texas Treasury Safekeeping Trust Company. She noted that the Texas Treasury Safekeeping Trust Company has expertise in asset management and the Oversight Committee previously approved a similar resolution regarding four other assets in August 2017.

MOTION:

On a motion made by Dr. Rice and seconded by Vice Presiding Officer Margo, the Oversight Committee unanimously voted to approve the resolution transferring asset management and disposition authority for AlloVir to the Texas Treasury Safekeeping Trust Company and for the payment of a fee.

Amendments to 25 T.A.C. Chapter 703 – Item 17, Tab 14

Presiding Officer Montgomery recognized CPRIT staff attorney Cameron Eckel to present the proposed administrative rule changes. Ms. Eckel addressed the proposed amendments affecting Texas Administrative Code Chapter 703 rules and CPRIT’s request to publish proposed changes to Chapter 703 rules.

MOTION:

On a motion by Vice Presiding Officer Margo and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the final order adopting rule changes to the Texas Administrative Code Chapter 703.

MOTION:

On a motion by Vice Presiding Officer Margo and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the publication of the proposed changes to Chapter 703 in the *Texas Register*.

Chief Operating Officer Report – Agenda Item 18, Tab 15

Presiding Officer Montgomery recognized Chief Operating Officer Heidi McConnell to review the third quarter FY 2019 budget expenditures. She also provided an update on the 2020 CPRIT conference as well as the FY 2020 budget.

An Oversight Committee member asked about the interest rate on CPRIT bonds. Ms. McConnell responded it was 3.7% for general obligation bonds and 2 - 4% for commercial paper.

Contract Approvals – Agenda Item 19, Tab 16

Ms. McConnell presented the FY 2020 service contract approvals.

She explained that the amendment to the SRA International contract is necessary because CPRIT has added a second review cycle for FY 2020. A base contract with SRA will be in place September 1 because CPRIT has previously received Legislative Budget Board approval for the base contract.

An Oversight Committee member asked how the new contract amounts compared to the previous contracts for economic assessment and internal audit services. Ms. McConnell responded that the economic assessment services contract with The Perryman Group increased by \$15,000 and that the internal services contract with Weaver and Tidwell increased about \$12,000 to \$14,000.

Ms. Doyle noted that the Texas Treasury Safekeeping Trust Company interagency agreement is for an amount not to exceed \$150,000; the final amount will depend upon the number of companies the Oversight Committee approves to transfer to the Trust Company for management in FY 2020.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the contracts with SRA International; ICON Clinical Research;

Hahn Public Communications; Vinson & Elkins, Baker Botts, and Yudell Isidore; The Perryman Group; Weaver and Tidwell; and the Texas Treasury Safekeeping Trust Company.

Subcommittee Business – Agenda Item 20, Tab 17

Presiding Officer Montgomery presented the FY 2020 – 2021 Subcommittee assignment recommendations.

MOTION:

On a motion made by Dr. Rice and seconded by Vice Presiding Officer Margo, the Oversight Committee voted to approve the new subcommittee assignments for FY 2020-2021.

Election of Board Officers – Agenda Item 22, Tab 18

Presiding Officer Montgomery presented the slate of Oversight Committee officer candidates recommended by the Nominations Subcommittee to serve FY 2020 - 2021.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the proposed slate of officers for FY 2020 and 2021: Dee Margo as Presiding Officer, Dr. Mahendra Patel as Vice Presiding Officer, and Dr. David Cummings as Secretary.

Following the vote, Mr. Roberts expressed CPRIT’s gratitude for Presiding Officer Montgomery’s service to the Oversight Committee and the agency. He presented Mr. Montgomery with an engraved gavel memorializing his tenure as presiding officer.

Presiding Officer Montgomery thanked Mr. Roberts and the Oversight Committee for CPRIT’s support and for the recognition.

Compliance Investigation Pursuant to Health & Safety Code 102.2631 – Agenda Item 23

Not taken up.

Consultation with General Counsel – Agenda Item 24

Not taken up.

Future Meeting Dates and Agenda Items – Agenda Item 25, Tab 19

Presiding Officer Montgomery directed the members to the FY 2020 Meeting Dates behind tab 19 of the meeting packet.

MOTION:

On a motion made by Vice Presiding Officer Margo and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the proposed meeting dates for the regular meetings of the Oversight Committee and the subcommittees for FY 2020.

Personnel – Agenda Item 21

Compliance Investigation Pursuant to Health and Safety Code 102.2631 – Agenda Item 23

Presiding Officer Montgomery announced that the Oversight Committee would go into closed session pursuant to Texas Open Meetings Act Section 551.074 and Texas Health & Safety Code Section 102.2631 to discuss personnel and an ongoing compliance investigation. He asked Mr. Roberts, Ms. Doyle, Mr. Burgess and Dr. Willson to join the Oversight Committee in closed session.

Presiding Officer Montgomery convened the closed session at 11:18 a.m. and reconvened the open meeting at 11:40 a.m. Regarding Agenda Item 21, Presiding Officer Montgomery called for a vote on Chief Executive Officer Wayne Roberts’ salary

MOTION:

On a motion by Dr. Rice and seconded by Dr. Patel, the Oversight Committee unanimously voted to approve an increase to Chief Executive Officer Wayne Roberts’ annual salary to \$281,875 effective September 1, 2019.

Presiding Officer Montgomery noted for the record that there was no action on Agenda Item 23 following the close session discussion.

Adjournment – Agenda Item 26

MOTION:

There being no further business, the Oversight Committee unanimously approved a motion to adjourn made by Presiding Officer Montgomery and seconded Dr. Angelou.

Meeting adjourned at 11:42 p.m.

Signature



Date

11/20/19